In a study conducted in an experimental model of epilepsy in mice, the compounds prevented seizures and their damaging effects on dendritic spines, specialised structures that allow brain cells to communicate, researchers said.
In epilepsy, these structures are damaged and rewire incorrectly, creating brain circuits that are hyper-connected and prone to seizures, they said.
"In the current study, preservation of dendritic spines and subsequent protection from seizures, were observed up to 100 days post-treatment, suggesting the process of epilepsy development has been arrested," said Nicolas Bazan from Louisiana State University (LSU) in the US.
A number of LAU compounds were studied, which blocked a neuroinflammatory signalling receptor, protecting dendritic spines and lessening seizure susceptibility and onset, as well as hyper-excitability, researchers including Surijyadipta Bhattacharjee and Chittalsinh M Raulji from LSU said.
In epilepsy, the normal pattern of neuronal activity becomes disturbed, causing strange sensations, emotions, and behaviour or sometimes convulsions, muscle spasms, and loss of consciousness, researchers said.
It is not uncommon for people with epilepsy, especially children, to develop behavioural and emotional problems in conjunction with seizures.
For many people with epilepsy, the risk of seizures restricts their independence and recreational activities. Epilepsy can be a life-threatening condition.
Some people with epilepsy are at special risk for abnormally prolonged seizures or sudden unexplained death in epilepsy. There is currently no cure, researchers said.
"Most of the anti-epileptic drugs currently available treat the symptom - seizures - not the disease itself," said Bazan.
"Understanding the potential therapeutic usefulness of compounds that may interrupt the development process may pave the way for disease-modifying treatments for patients at risk for epilepsy," he said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
